These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 24011281

  • 1. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE, Watson AC, Aronson P.
    Dermatol Online J; 2013 May 15; 19(5):18184. PubMed ID: 24011281
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
    Sil A, Das NK.
    Indian J Pharmacol; 2014 May 15; 46(3):334-6. PubMed ID: 24987183
    [Abstract] [Full Text] [Related]

  • 3. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E, Rigau V, Pageaux GP, Guillot B, Kluger N.
    Cutis; 2014 Jan 15; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract] [Full Text] [Related]

  • 4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov 15; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, Daido Y.
    Keio J Med; 2015 Nov 15; 64(4):62-4. PubMed ID: 26727578
    [Abstract] [Full Text] [Related]

  • 14. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2013 Jul 15; 33(6):950-7. PubMed ID: 23601249
    [Abstract] [Full Text] [Related]

  • 15. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Dasanu CA, Alexandrescu DT, Dutcher J.
    South Med J; 2007 Mar 15; 100(3):328-30. PubMed ID: 17396743
    [Abstract] [Full Text] [Related]

  • 16. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW.
    Dermatol Surg; 2013 Jul 15; 39(7):981-7. PubMed ID: 23464361
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, Moehler T, Goldschmidt H, Schmidt-Wolf IG.
    Hematol Oncol; 2013 Dec 15; 31(4):197-200. PubMed ID: 23494836
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.